Juniper Pharmaceuticals Inc.
www.juniperpharma.com
Latest From Juniper Pharmaceuticals Inc.
Pipeline Review: Large Potential Overactive Bladder Population Beckons
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Execs On The Move, January 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Execs On The Move, May 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
-
Biotechnology
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
-
Drug Delivery
- Services
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Alias(es)
- Columbia Laboratories Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Juniper Pharmaceuticals Inc.
- Senior Management
-
Alicia Secor , Pres. & CEO
Jeffrey Young, CFO, Treasurer & Secretary
Nikin Patel, PhD, COO
Shen Luk, PhD, CSO - Contact Info
-
Juniper Pharmaceuticals Inc.
Phone: (617) 639-1500
33 Arch St., 31st Fl.
Ste. 3110
Boston, MA 02110
USA